Anti-mCTLA4-mIgG2a InvivoFit™ is a mouse anti-mouse monoclonal antibody (mAb) featuring the variable region of the previously described anti-mCTLA-4 9D9 mAb [1] and a murine IgG2a constant region. The 9D9 mAb has a sequence that is 100% murine (constant and variable regions), ensuring minimal immunogenicity upon repeated injections into mice. This mAb targets murine cytotoxic T-lymphocyte-associated protein 4 (mCTLA-4) and blocks CTLA4-mediated negative signals downregulating T cell activation. Thus, anti-mCTLA-4 mAb unleashes T cell activity [1, 2].
Notably, the 9D9 mAb, along with the most commercially available anti-mCTLA4 mAbs feature the IgG2b isotype which displays low antitumor activity in vivo [2]. To overcome this issue, Anti-mCTLA4-mIgG2a InvivoFit™ was generated by recombinant technology and features the murine IgG2a isotype, which mediates potent cytotoxic functions. Anti-mCTLA4-mIgG2a is provided in an InvivoFit™ grade, a high-quality standard specifically adapted to in vivo studies.
Key features of Anti-mCTLA4-mIgG2a InvivoFit™:
- Sequence is 100% murine
- Features the IgG2a isotype (associated with high antitumor activity)
- Guaranteed sterile, endotoxin level < 1 EU/mg
- Specifically designed for in vivo studies in mice
- Low aggregation < 5%
- Produced in animal-free facilities and defined media
Anti-mCTLA4-mIgG2a InvivoFit™ is produced in Chinese hamster ovary (CHO) cells, purified by affinity chromatography with protein A, and it's binding to mCTLA-4 is validated using ELISA.
References:
- Selby MJ. et al., 2013. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res. 1(1):32-42.
- Ribas A. & Wolchock J.D., 2018. Cancer immunotherapy using checkpoint blockade. Science. 359:1350-55.
